Mereo BioPharma
MREO
63 hedge funds and large institutions have $212M invested in Mereo BioPharma in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 17 closing their positions.
2.7% more ownership
Funds ownership: 13.55% → 16.24% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 71 → 63 (-8)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
25% less capital invested
Capital invested by funds: $283M → $212M (-$71M)
40% less call options, than puts
Call options by funds: $237K | Put options by funds: $392K
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$45.7M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$14.9M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.11M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.97M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$19.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$5.74M |
| 3 |
PA
Perceptive Advisors
New York
|
-$5.38M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$5.13M |
| 5 |
TLP
Tri Locum Partners
New York
|
-$3.97M |
MREO Hedge Fund Activity: Q3 2021 in Review
63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2021, worth a combined $212M — down 25% from $283M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MREO and 9 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 16 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $45.7M. The largest seller was Boxer Capital, exiting entirely with an estimated $19.7M sold.
- 63 institutional investors held Mereo BioPharma (MREO) as of Q3 2021, down from 71 in Q2 2021.
- Funds reported $212M of Mereo BioPharma stock for Q3 2021, down 25% quarter-over-quarter.
- 9 funds opened new Mereo BioPharma positions in Q3 2021 and 17 closed out, a net change of -8 holders.
- The largest Mereo BioPharma buyer in Q3 2021 was OrbiMed, an estimated $45.7M added.
- The largest Mereo BioPharma seller in Q3 2021 was Boxer Capital, an estimated $19.7M sold.
Based on aggregated 13F filings for Q3 2021.